Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study
You are responsible for safe and proper use
Labeling 2,000 islets produced a readily detectable hypointense focus on 3 T MRI, whereas non-targeted SPIONs generated no contrast [120]
Although not approved for these conditions, they have also shown promise for addiction and substance use disorders, as well as Alzheimers disease and dementia
Yes, GLP-1 is a hormone that is being developed as an anti-obesity drug (this was published two years before Ozempic)
It is why they work for some patients and not others, and what the biology of non-response is revealing about the mechanism